VIENNA, May 5, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that the company's Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011.

VIENNA, March 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs. Increase in IXIARO®/JESPECT® sales by approximately 66% to EUR 12.8m for the full year 2010, due to increased sales in key travel markets and to U.S.

VIENNA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Today, Intercell AG (VSE: ICLL) announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

VIENNA, Aug.

VIENNA, May 11 /PRNewswire-FirstCall/ -- Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's development programs. Financial Results EUR 4.8m revenues in Q1 2010 compared to EUR 5.4m in Q1 2009.IXIARO®/JESPECT® product sales in line with Q1 2009 reflecting low level of new product supplies in Q1 2010; new product supplies to marketing and distribution partners shifted from Q1 to Q2 2010 due to supply-planning and lot release timing.EUR 14.7m net loss for Q1 2010 compared to EUR 8.2m in Q1 2009.EUR 17.9m R&D expenses in Q1 2010 - up 19.1 percent compared to EUR 15.1m in Q1 2009 - mainly due to late-stage research and development costs for the TD vaccine patch.Strong cash position: EUR 158.2m in liquid funds at March 31, 2010. Key Financial Figures 3 months ended Year ended EUR in thousands -------------- -----